RESPIRATORY CARE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In January 2023, Synergy Life Science, Inc., a healthcare company, announced the launch of Nebi, the first pocket-sized and fully battery-operated nebulizer for use in a variety of applications. Nebi is an effective, on-the-go method for medication delivery, recreational uses, and is a safe alternative to vaping for smoking cessation.
• In November 2022, Reckitt Benckiser Group plc, a U.K.-based multinational consumer goods company, launched a new education and early detection campaign for patients with undiagnosed chronic obstructive pulmonary disease (COPD)
• In February 2022, AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, and Honeywell International Inc., a U.S.-based publicly traded, multinational conglomerate corporation, announced that they are set to collaborate in the development of advanced respiratory inhalers (pressurized metered dose inhalers (pMDIs)), utilizing the propellant HFO-1234ze. This particular propellant exhibits a significantly low Global Warming Potential (GWP) when compared to the propellants currently employed in respiratory medications, with a potential reduction of up to 99.9%.
• In September 2021, European Respiratory Society (ERS), the Global Allergy and Airways Patient Platform (GAAPP), AstraZeneca, Amgen, and leading respiratory clinicians launched the International Respiratory Coalition, a new partnership to transform post-pandemic respiratory healthcare
• In March 2021, PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announced the authorization of the LAMIRA Nebulizer System for the delivery of Insmed's drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. LAMIRA is the first drug-specific eFlow Technology nebulizer registered beyond Europe and North America.